Schrodinger

SDGR

Market cap $1.3B

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) provided an update on its progress across the business in 2025 and announced its strategic priorities for 2026. The company is continuing to focus on advancing its physics+AI computational platform and serving as a global leader in computational molecular discovery. “In 2025, we witnessed the continued impact of scaling ‘physics+AI' to solve the challenges of data scarcity and to accelerate the discovery of differentiated molecules. We.

Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, on its drug designing software.

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced a collaboration with Lilly TuneLab™, a platform launched by Eli Lilly and Company (Lilly) designed to accelerate drug discovery and development by providing access to advanced artificial intelligence (AI) capabilities. TuneLab will be made available in LiveDesign, Schrödinger's widely used enterprise informatics platform, as a priority interface for participating biotech companies to access TuneLab workflows. “As a lead.

She and her team loaded up on two cryptocurrency-related companies. They also purchased an innovative healthcare tech stock.

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on December 15, 2025, the company granted restricted stock units (RSUs) with respect to 2,666 shares of the company's common stock to 6 newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement t.

The consensus price target hints at a 46.2% upside potential for Schrodinger (SDGR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Schrodinger's shares have declined sharply in recent weeks, due largely to soft guidance for the fourth quarter. There is little reason to believe that this is anything more than a temporary headwind caused by market conditions though. In addition, recent cost reductions and the end of internal drug development should significantly reduce cash burn in 2026.

Schrodinger (SDGR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference. The live presentation will take place on Wednesday, November 19, at 4:00 p.m. GMT (11:00 a.m. ET). The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with i.

Schrödinger, Inc. ( SDGR ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Jaren Madden - Chief Corporate Affairs Officer & Head of Investor Relations Ramy Farid - CEO, President & Director Richie Jain - Executive VP, CFO & Treasurer Karen Akinsanya - President, Head of Therapeutics R&D and Chief Strategy Officer & Partnerships Conference Call Participants Mani Foroohar - Leerink Partners LLC, Research Division Scott Schoenhaus - KeyBanc Capital Markets Inc., Research Division Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Conor MacKay - BMO Capital Markets Equity Research Dennis Ding Brendan Smith - TD Cowen, Research Division Michael Ryskin - BofA Securities, Research Division Presentation Operator Thank you for standing by. Welcome to Schrodinger's conference call to review third quarter 2025 financial results.